On July 13, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that Company manufacturing leadership will present sessions on cutting edge topics in lipid-based nanoparticle delivery systems at the upcoming Next Generation Lipid-Based Nanoparticles Delivery Summit taking place from July 19-21, 2022 in Boston (Press release, Genprex, JUL 13, 2022, View Source [SID1234616706]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are extremely fortunate to have our critical manufacturing function led by Dr. Kumar and his talented team, including Dr. Shinde, and are pleased to see their well-deserved recognition as thought leaders in the rapidly evolving field of lipid nanoparticle delivery of therapeutics," said Rodney Varner, President and Chief Executive Officer of Genprex. "As we advance our lead development program in non-small cell lung cancer in Phase 1/2 clinical studies, it is more important than ever to have our gene therapy manufacturing in such capable hands and we are proud of our exceptional team."

On July 13, 2022 Anumana, Inc., an AI-driven health technology company and portfolio company of nference, reported that it has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation ("Novartis") to deploy a series of artificial intelligence (AI)-powered software solutions that will detect hidden cardiovascular conditions (Press release, Novartis, JUL 13, 2022, View Source [SID1234616678]). The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration will support Anumana’s efforts to implement AI-enabled diagnostic software that can detect signals from ECGs that humans cannot interpret. The collaboration will initially focus on cardiovascular diseases. Working with its expert partners from Mayo Clinic, Anumana will deploy novel solutions that use AI to analyze an ECG, a widely available, painless test that records the heart’s electrical signals to identify undiagnosed left ventricular dysfunction, or a weak heart pump, which can lead to heart failure. The AI will also screen for atherosclerotic cardiovascular disease, which can lead to heart attack and stroke. In addition, an evidence-based, digital point-of-care solution will be developed to guide in optimizing guideline-directed medical therapies with the aim to lower risk for potentially avoidable hospitalizations and cardiovascular death.

"Anumana technology is designed to help physicians identify patients who are at maximum risk of heart failure, long before they develop symptoms," said Murali Aravamudan, CEO of Anumana. "Bringing together premier global organizations will allow us to expand access to best-in-class, AI-powered digital tools to benefit patients through earlier detection and intervention, when and where health care providers need it most."

"Many heart diseases develop for years before signs and symptoms appear, but the first event may be life threatening," said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. "AI enables us to uncover hidden signals our bodies transmit to detect otherwise occult heart diseases, potentially years before symptoms appear. This collaboration has the potential to transform the use of an ubiquitous inexpensive test, the ECG, with the aim of democratizing disease detection and helping medical care teams to proactively manage heart disease ahead of time and prevent some clinical events from ever happening."

"Cardiovascular disease is a widespread and multifactorial disease and, in order to mitigate its impact, we must look beyond therapeutic innovation and reimagine how we approach cardiovascular care," said Victor Bulto, President, Novartis Innovative Medicines US. "Novartis is proud to collaborate with Anumana on innovative and data-driven solutions to better predict the risk of life-threatening heart disease, further driving forward our commitment to improving patient experiences and population health outcomes in this patient population."

The Mayo Clinic Cardiology team, led by Dr. Friedman, pioneered the application of AI in cardiology and developed several algorithms based on millions of ECGs, including a low ejection fraction algorithm that received FDA Breakthrough Device Designation in 2019 and Emergency Use Authorization for COVID-19 in 2020. Further validating the technology, a recent study presented by Mayo Clinic used a modified version of Anumana’s 12-lead ECG algorithm to detect left ventricular dysfunction with single-lead ECGs in smartwatches. These algorithms are licensed to Anumana for development of clinical solutions and have been validated by over 30 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021. These software solutions are currently in development with each algorithm as a candidate for marketing authorization through an FDA DeNovo request.

On July 13, 2022 Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, reported that updates related to the ongoing clinical programs for sapanisertib (CB-228) and mivavotinib (CB-659) will be presented at the upcoming International Association for Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) and the 2022 Pan Pacific Lymphoma Conference, respectively (Press release, Calithera Biosciences, JUL 13, 2022, View Source [SID1234616665]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Following our recent announcements that we’ve enrolled patients in both the mivavotinib and sapanisertib clinical trials, we are pleased that details of the mivavotinib trial-in-progress will be shared with the esteemed group of lymphoma physicians who attend the Pan Pacific Lymphoma Conference," said Susan Molineaux, PhD, president and chief executive officer of Calithera. "We are also very interested in the data collected by Dr. Jonathan Riess and colleagues in the investigator-led phase 1 trial combining sapanisertib with telaglenastat in patients with non-small cell lung cancer, particularly given that we are evaluating sapanisertib in patients with NRF2-mutated squamous non-small cell lung cancer in our own, ongoing company-sponsored trial.

"We’re proud of the progress we’ve continued to make in both the sapanisertib and mivavotinib clinical programs since we acquired these compounds late last year, and believe they have the potential to be first-in-class treatments addressing areas of high unmet need," said Molineaux.

During the Pan Pacific Lymphoma Conference taking place July 18-22 in Koloa, Hawaii, Reem Karmali, MD, MS, associate professor of Medicine at Northwestern University, will present a poster detailing the trial design of Calithera’s phase 2 study of mivavotinib, a spleen tyrosine kinase (SYK) inhibitor. The phase 2 trial (NCT05319028), which enrolled its first patient in June, is an open-label study of mivavotinib monotherapy in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma (DLBCL). The main objectives of the study are to confirm previously seen single-agent activity in non-GCB DLBCL patients, evaluate activity according to MYD88/CD79b mutational status, and refine dose/schedule in this patient population. Approximately 50 non-GCB DLBCL patients, with or without MYD88/CD79b mutations, will be randomized 1:1 to one of two oral dose/schedule cohorts: a continuous dosing schedule (100 mg QD) or an induction dosing schedule (120 mg QD x 14 days, then 80 mg QD starting Day 15). Data from this trial could position Calithera to initiate a study with registrational intent in biomarker-specific DLBCL populations.

During an August 9 mini oral session at IASLC/2022 WCLC, Jonathan W. Riess, MD, MS, director of Thoracic Oncology and associate professor at UC Davis Comprehensive Cancer Center, will present dose-escalation findings from a multi-center phase 1/2 investigator-initiated study evaluating sapanisertib, a potent and selective dual mTORC 1/2 inhibitor, in combination with telaglenastat (CB-839), a novel, investigational glutaminase inhibitor, in biomarker-defined cohorts of patients with advanced non-small cell lung cancer (NSCLC). Sapanisertib targets a key survival mechanism in tumors harboring NRF2 mutations, which are found in a considerable sub-population of patients across multiple solid tumor types and are generally associated with a poorer prognosis. In pre-clinical studies, combining sapanisertib and telaglenastat showed synergistic anti-tumor activity.

After evaluating five combination dosing levels in 13 patients, researchers determined that the sapanisertib/telaglenastat combination is safe and tolerable at the recommended expansion dose (2 mg sapanisertib once daily, 800 mg telaglenastat twice daily). Researchers also observed tumor shrinkage among the majority of evaluable patients (5/8), including patients with lung cancers harboring KEAP1 or NRF2 mutations. As a next step, study investigators plan to enroll patients into one of four expansion cohorts evaluating sapanisertib plus telaglenastat in squamous NSCLC with and without NRF2 or KEAP1 mutations, and adenocarcinoma NSCLC with KRAS and KEAP1 or NRF2 mutations.

On July 13, 2022 Amgen reported that Early data from it’s ongoing trial on Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) hinted at positive results from what could be a transformative combination of drugs versus cancer (Press release, BioSpace, JUL 13, 2022, View Source [SID1234616664]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to Reuters, data is still on hold until August 7, and key details aren’t yet available. Amgen’s study is evaluating how Lumakras will perform when used alongside existing immunotherapies, such as Roche’s Tecentriq and Merck’s Keytruda. Industry observers are looking forward to the data, as the study is the first to showcase how this combination will fare at the World Conference on Lung Cancer (WCLC) in Vienna from August 6 to 9.

In an oral presentation on Lumakras at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting in early June, Amgen shared positive early data from its Phase I/II study on the safety and efficacy of the drug for patients with pancreatic cancer. It was then that the company shared that it is also conducting a Phase II trial on Lumakras as a first-line treatment for people diagnosed with stage IV NSCLC whose tumors harbor a KRAS p.G12C mutation.

"Amgen continues to lead the science in KRASG12C inhibition and is committed to advancing research into how Lumakras can improve outcomes for more patients, including further defining resistance patterns to guide our robust combination treatment development program," David M. Reese, M.D., the executive vice president of research and development at Amgen said.

The U.S. Food and Drug Administration approved Lumakras in 2021 under accelerated approval for the treatment of advanced lung cancer cases with KRAS mutations whose conditions have worsened after receiving chemotherapy and other medications. In January this year, the Japanese government gave the green light for its healthcare system to use the drug for positive, unresectable, advanced and/or recurrent NSCLC that has progressed after systemic anticancer interventions.

"In just over three years since the first patient was dosed in the pivotal CodeBreaK 100 trial, LUMAKRAS is now approved in nearly 40 countries, illustrating our commitment to accelerating transformative medicines for patients living with cancers that have yet to be fully addressed," Reese stated.

"KRAS has challenged cancer researchers for more than 40 years, with many deeming it as ‘undruggable.’ The Lumakras development program was a race against cancer for Amgen’s scientists and clinical trial investigators who together have now successfully delivered this new medicine to patients in less than three years—from the first patient dosed to U.S. regulatory approval," Dr. Reese also said.

The approvals are based on positive results from the Phase II CodeBreak 100 trial in NSCLC. Lumakras is a 960 mg, orally administered drug given once a day. The latest study to be presented at WCLC will highlight the drug’s potency when combined with other existing medications.

On July 13, 2022 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported it will present two posters for its parallel lead programs, NVL-655, an ALK-selective inhibitor and NVL-520, a ROS1-selective inhibitor, at the IASLC 2022 World Conference on Lung Cancer (WCLC) Annual Meeting taking place August 6-9, 2022 in Vienna, Austria (Press release, Nuvalent, JUL 13, 2022, View Source [SID1234616663]). Posters will be archived on the Nuvalent website at www.nuvalent.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first poster characterizes NVL-655 alongside other ALK inhibitors in a patient-derived model of lorlatinib-resistant ALK-positive non-small cell lung cancer (NSCLC) with the treatment-emergent G1202R/T1151M compound resistance mutation. NVL-655 has previously demonstrated differentiation through broad preclinical activity across diverse ALK oncoproteins, resistance mutations, and tumor types while maintaining strong selectivity for ALK over TRKB. Nuvalent recently announced the first patient has been dosed with NVL-655 in the ALKOVE-1 Phase 1/2 study for patients with advanced ALK-positive NSCLC and other solid tumors.

A "Trial in Progress" poster will also be presented with background and study design for the ongoing ARROS-1 Phase 1/2 study of NVL-520 for patients with advanced ROS1-positive NSCLC and other solid tumors. The multicenter, open-label, dose-escalation and expansion trial is currently evaluating NVL-520 as an oral monotherapy in the Phase 1 portion of the study. Nuvalent plans to share preliminary dose-escalation data from ARROS-1 in the second half of 2022.

Details for the E-poster presentations are as follows:

Title: Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation
Authors: H. Mizuta1, L. Bigot1, A. Tangpeerachaikul2, H.E. Pelish2, L. Friboulet1
Abstract Number: EP08.02-020
Session Category: Metastatic Non-small Cell Lung Cancer
Session Title: Molecular Targeted Treatments
Session Date and Time: August 7, 2022, 9:45am – 6:00pm CEST

1Gustave-Roussy, Villejuif, France; 2Nuvalent, Inc., Cambridge, MA, USA

Title: NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study
Authors: A. Drilon1, S-H.I. Ou2, S. Gadgeel3, M. Johnson4, A. Spira5, G. Lopes6, B. Besse7, E. Felip8, A.J. van der Wekken9, A. Calles10, M.J. de Miguel11, D.R. Camidge12, Y. Elamin13, S. Liu14, J. Bauman15, D. Haggstrom16, G. Riley17, H.E. Pelish17, V.W. Zhu17, J.J. Lin18
Abstract Number: EP08.02-041
Session Category: Metastatic Non-small Cell Lung Cancer
Session Title: Molecular Targeted Treatments
Session Date and Time: August 7, 2022, 9:45am – 6:00pm CEST

1Memorial Sloan Kettering Cancer Center, New York/NY/USA ,2University Of California Irvine Medical Center, Orange/CA/USA ,3Henry Ford Cancer Institute, Detroit/MI/USA ,4Sarah Cannon Research Institute, Nashville/TN/USA,5NEXT Oncology – Virginia Cancer Specialists, Fairfax/VA/USA ,6Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami/FL/USA ,7Institut Gustave Roussy, Villejuif Cedex/FR,8Hospital Vall d’Hebron, Barcelona/ES ,9University of Groningen, University Medical Centre Groningen,Groningen/NL ,10Hospital Universitario Gregorio Marañón, Madrid/ES,11 START Madrid-HM CIOCC, Madrid/ES,12University of Colorado Cancer Center, Anschutz Medical Campus, Aurora/CO/USA ,13MD Anderson Cancer Center, Houston/TX/USA ,14Georgetown University, Washington/DC/USA ,15Fox Chase Cancer Center, Philadelphia/PA/USA,16Levine Cancer Institute, Atrium Health, Charlotte/NC/USA ,17Nuvalent, Inc., Cambridge/MA/USA ,18Massachusetts General Hospital, Boston/MA/USA

About NVL-655

NVL-655 is a novel brain-penetrant ALK-selective inhibitor created to overcome limitations observed with currently available ALK inhibitors. NVL-655 is designed to remain active in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or compound mutations G1202R / L1196M ("GRLM"), G1202R / G1269A ("GRGA"), or G1202R/L1198F ("GRLF"). NVL-655 has been optimized for CNS penetrance to improve treatment options for patients with brain metastases. NVL-655 has been observed in preclinical studies to selectively inhibit wild-type ALK and its resistance variants over the structurally related tropomyosin receptor kinase (TRK) family to potentially avoid TRK-related CNS adverse events seen with dual TRK/ALK inhibitors and drive more durable responses for patients. NVL-655 is currently being investigated in the ALKOVE-1 study (NCT05384626), a first-in-human Phase 1/2 clinical trial for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors.

About NVL-520

NVL-520 is a novel brain-penetrant ROS1-selective inhibitor designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with the prevalent G2032R resistance mutation and those with the S1986Y/F, L2026M, or D2033N resistance mutations. NVL-520 has been optimized for brain penetrance to potentially improve treatment options for patients with brain metastases. NVL-520 has been observed in preclinical studies to selectively inhibit wild-type ROS1 and its resistance variants over the structurally related tropomyosin receptor kinase (TRK) family to potentially avoid TRK-related CNS adverse events seen with dual TRK/ROS1 inhibitors and drive more durable responses for patients. NVL-520 is currently being investigated in the ARROS-1 study (NCT05118789), a first-in-human Phase 1/2 clinical trial for patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.